Related Experiment Video
Updated: Jun 9, 2025
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
Immunotherapy Vaccines for Prostate Cancer Treatment
Jide He1, Jialong Wu1, Ziang Li1
1Department of Urology, Peking University Third Hospital, Beijing, China.
Background:
Therapeutic tumor vaccines have emerged as a compelling avenue for treating patients afflicted with advanced prostate cancer (PCa), particularly those experiencing biochemical relapse or ineligible for surgical intervention. This study serves to consolidate recent research findings on therapeutic vaccines targeting prostate tumors while delineating prevalent challenges within vaccine research and development.
Methods:
We searched electronic databases, including PubMed, Web of Science, Embase, and Scopus, up to August 31, 2024, using keywords such as 'vaccine', 'prostate cancer', 'immunotherapy', and others. We reviewed studies on various therapeutic vaccines, including dendritic cell-based, antigen, nucleic acid, and tumor cell vaccines.
Results:
Studies consistently showed that therapeutic vaccines, notably DC vaccines, had favorable safety profiles with few adverse effects. These vaccines, with varied antigenic formulations, demonstrated strong clinical outcomes, as indicated by metrics such as PSA response rates (9.5%-58%), extended PSA doubling times (52.9%-89.7%), overall survival durations (17.7-33.8 months), two-year mortality rates (0%-12.5%), biochemical relapse rates (42%-73%), and antigen-specific immune responses (33.3%-71.4% in responsive groups).
Conclusion:
While clinical data for tumor vaccines have illuminated robust evidence of tumoricidal activity, the processes of their formulation and deployment are riddled with complexities. Combining vaccines with other therapies may enhance outcomes, and future research should focus on early interventions and deciphering the immune system's role in oncogenesis.
Insights
Therapeutic prostate cancer (PCa) vaccines show promise for advanced disease, particularly in cases of relapse. While effective, challenges in formulation and deployment persist, suggesting combination therapies and early intervention are key for future research.
Area of Science:
- Oncology
- Immunology
- Vaccinology
Background:
- Therapeutic tumor vaccines offer a promising treatment for advanced prostate cancer (PCa), especially for patients with biochemical relapse or those unsuitable for surgery.
- This review consolidates current research on therapeutic vaccines for prostate tumors and identifies challenges in their development.
Purpose of the Study:
- To review and synthesize recent findings on therapeutic vaccines for prostate cancer.
- To delineate challenges in the research and development of prostate cancer vaccines.
Main Methods:
- A systematic literature search was conducted in PubMed, Web of Science, Embase, and Scopus up to August 31, 2024.
- Keywords included 'vaccine', 'prostate cancer', and 'immunotherapy'.
- Studies on various vaccine types (dendritic cell-based, antigen, nucleic acid, tumor cell) were reviewed.
Main Results:
- Therapeutic vaccines, particularly dendritic cell (DC) vaccines, exhibit favorable safety profiles with minimal adverse effects.
- These vaccines demonstrate significant clinical efficacy, with reported outcomes including PSA response rates (9.5%-58%), extended PSA doubling times (52.9%-89.7%), and improved overall survival (17.7-33.8 months).
- Other notable results include low two-year mortality rates (0%-12.5%), reduced biochemical relapse rates (42%-73%), and significant antigen-specific immune responses (33.3%-71.4%).
Conclusions:
- Clinical data confirm the tumoricidal activity of therapeutic vaccines, despite formulation and deployment complexities.
- Combining vaccines with other therapeutic modalities may improve patient outcomes.
- Future research should prioritize early intervention strategies and investigate the role of the immune system in prostate cancer development.
Related Concept Videos
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
01:27Tumor Immunotherapy
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:29Microorganisms in Medicine and Therapeutics